Inhibition of the Eukaryotic Initiation Factor-2-α Kinase PERK Decreases Risk of Autoimmune Diabetes in Mice

Charanya Muralidharan,Fei Huang,Jacob R Enriquez,Jiayi E Wang,Jennifer B Nelson,Titli Nargis,Sarah C May,Advaita Chakraborty,Kayla T Figatner,Svetalana Navitskaya,Cara M Anderson,Veronica Calvo,David Surguladze,Mark J Mulvihill,Xiaoyan Yi,Soumyadeep Sarkar,Scott A Oakes,Bobbie-Jo M Webb-Robertson,Emily K Sims,Kirk A Staschke,Decio L Eizirik,Ernesto S Nakayasu,Michael E Stokes,Sarah A Tersey,Raghavendra G Mirmira

DOI: https://doi.org/10.1101/2023.10.06.561126

2024-06-03

Abstract:Preventing the onset of autoimmune type 1 diabetes (T1D) is feasible through pharmacological interventions that target molecular stress-responsive mechanisms. Cellular stresses, such as nutrient deficiency, viral infection, or unfolded proteins, trigger the integrated stress response (ISR), which curtails protein synthesis by phosphorylating eIF2α. In T1D, maladaptive unfolded protein response (UPR) in insulin-producing β cells renders these cells susceptible to autoimmunity. We show that inhibition of the eIF2α kinase PERK, a common component of the UPR and ISR, reverses the mRNA translation block in stressed human islets and delays the onset of diabetes, reduces islet inflammation, and preserves β cell mass in T1D-susceptible mice. Single-cell RNA sequencing of islets from PERK-inhibited mice shows reductions in the UPR and PERK signaling pathways and alterations in antigen processing and presentation pathways in β cells. Spatial proteomics of islets from these mice shows an increase in the immune checkpoint protein PD-L1 in β cells. Golgi membrane protein 1, whose levels increase following PERK inhibition in human islets and EndoC-βH1 human β cells, interacts with and stabilizes PD-L1. Collectively, our studies show that PERK activity enhances β cell immunogenicity, and inhibition of PERK may offer a strategy to prevent or delay the development of T1D.

Cell Biology

What problem does this paper attempt to address?

The paper attempts to address the issue of reducing the risk of autoimmune diabetes (T1D) in mice by inhibiting the eukaryotic initiation factor-2α kinase PERK. Specifically, the researchers explored the role of PERK in the pathogenesis of T1D and assessed the impact of PERK inhibitors on β-cell function and immune response. The main objectives of the paper include: 1. **Assessing the role of PERK in T1D**: The researchers hypothesized that sustained activation of PERK leads to β-cell dysfunction and increases their susceptibility to autoimmune attack. They tested this hypothesis by inhibiting PERK. 2. **Validating the effects of PERK inhibition**: Using a novel small molecule PERK inhibitor, HC-5770, the researchers evaluated the protective effects of PERK inhibition on β-cell translational blockade, islet inflammation, and β-cell mass. 3. **Exploring the molecular mechanisms of PERK inhibition**: The researchers conducted detailed analyses of the effects of PERK inhibition on β-cells and immune cells using techniques such as single-cell RNA sequencing and spatial proteomics, particularly focusing on the upregulation of PD-L1 levels and its regulatory role in immune response. 4. **Evaluating the long-term impact of PERK inhibition on diabetes development**: Through long-term treatment experiments, the researchers observed the long-term effects of PERK inhibition on the incidence of diabetes in mice to determine its efficacy as a potential strategy for preventing or delaying the development of T1D. Overall, the paper aims to reduce the risk of T1D by inhibiting PERK and to elucidate the specific role of PERK in the pathogenesis of T1D and its potential therapeutic significance.

Inhibition of the Eukaryotic Initiation Factor-2-α Kinase PERK Decreases Risk of Autoimmune Diabetes in Mice

Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice

Diabetes Mellitus and Exocrine Pancreatic Dysfunction in Perk-/- Mice Reveals A Role for Translational Control in Secretory Cell Survival

Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice

Inhibition of the Keap1/Nrf2 Signaling Pathway Significantly Promotes the Progression of Type 1 Diabetes Mellitus

Beyond Knockout: A Novel Homodimerization-Targeting MyD88 Inhibitor Prevents and Cures Type 1 Diabetes in NOD Mice

Synergistic Effect Of Erad And Autophagy In Preventing Proinsulin A Regation And Promoting Beta-Cell Survival

Modulation of Autophagy Influences the Function and Survival of Human Pancreatic Beta Cells Under Endoplasmic Reticulum Stress Conditions and in Type 2 Diabetes

Controlling autoimmune diabetes onset by targeting Protease-Activated Receptor 2

Immunopeptidome mining reveals a novel ERS-induced target in T1D

TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes

The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

Beta cell specific cannabinoid 1 receptor deletion counteracts progression to hyperglycemia in non-obese diabetic mice

Endoplasmic reticulum stress in pancreatic β cells induces incretin desensitization and β-cell dysfunction via ATF4-mediated PDE4D expression

Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function

Protection of beta cells against pro-inflammatory cytokine stress by the GDF15-ERBB2 signaling

A Novel Tolerogenic Antibody Targeting Disulfide-Modified Autoantigen Effectively Prevents Type 1 Diabetes in NOD Mice

Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes

Deletion of IRE1α in podocytes exacerbates diabetic nephropathy in mice

The translational content and expression of intracellular sensors under endoplasmic re-ticulum stress in diabetic rats

Bax Inhibitor-1 preserves pancreatic β-cell proteostasis by limiting proinsulin misfolding and programmed cell death